Alto Neuroscience (Alto Neuroscience) Debt-to-Equity : -0.14 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Debt-to-Equity?

Alto Neuroscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.13 Mil. Alto Neuroscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $9.86 Mil. Alto Neuroscience's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-71.67 Mil. Alto Neuroscience's debt to equity for the quarter that ended in Dec. 2023 was -0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Alto Neuroscience's Debt-to-Equity or its related term are showing as below:

ANRO' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.25 Med: -0.2 Max: -0.14
Current: -0.14

During the past 3 years, the highest Debt-to-Equity Ratio of Alto Neuroscience was -0.14. The lowest was -0.25. And the median was -0.20.

ANRO's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs ANRO: -0.14

Alto Neuroscience Debt-to-Equity Historical Data

The historical data trend for Alto Neuroscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Debt-to-Equity Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

-0.25

-0.14

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Debt-to-Equity	-	N/A	-0.25	-0.16	-0.14

Competitive Comparison of Alto Neuroscience's Debt-to-Equity

For the Biotechnology subindustry, Alto Neuroscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Debt-to-Equity falls into.

Alto Neuroscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Alto Neuroscience's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.125	+	9.861)	/	-71.672
	=	-0.14

Alto Neuroscience's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.125	+	9.861)	/	-71.672
	=	-0.14

Alto Neuroscience (NYSE:ANRO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Alto Neuroscience Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024